11/25/2020, 6:18 AM (Source: TeleTrader)
more TeleTrader news

Sinopharm seeks COVID vaccine authorization for public use

Sinopharm subsidiary China National Biotec Group (CNBG) submitted an application to Chinese regulators for the approval of its COVID-19 vaccine for public use, Xinhua Finance reported citing Sinopharm's vice general manager Shi Shengyi.

Earlier, Sinopharm stated it carried out Phase 3 trials involving over 50,000 people in 10 countries and noticed no serious adverse reaction to the coronavirus vaccine candidate.

The Chinese company added that nearly one million people already received its vaccine through the emergency use program.

Sinopharm shares listed in Hong Kong surged 6.42% at 6:05 am CET.

Breaking the News / NP